Kinnov Therapeutics, a spin-off in pharmaceutical development dedicated to combat against addiction

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction. Supported by experienced scientists in the drug discovery and development, we have identified a disruptive strategy to treat addicted people. KT-110, our first-in-class patented lead composition, enters phase 2 clinical trial for alcohol addiction. KT-110 associates two off-patent drugs demonstrating a synergistic effect on addiction.